GBC Invests in Auxesis Pharma Holding AB
Auxesis Develops Innovative Pain and Skin Irritation Treatments
Auxesis is developing pharmaceuticals that address a clear market gap: effective, over-the-counter treatments for pain and skin irritation. With a foundation in scientific excellence and a sustainability-driven strategy, the company aims to redefine a pharmaceutical category relevant to both humans and animals.
A Leading Product with Global Potential
The company’s primary innovation, ASA.P®, is the result of several years of research at the Karolinska Institute. Auxesis is the first in the world to stabilize acetylsalicylic acid (ASA) in liquid form, enabling topical application directly to the skin. The product blocks pain signals within minutes without entering the bloodstream and also possesses anti-inflammatory properties. The launch on the over-the-counter market is planned for 2026.
In addition to this, Auxesis is developing the veterinary product CoxyPet®, with the aim of treating pain in animals and reducing the reliance on antibiotics in veterinary care. The launch is planned for 2027.
With a patent pending for the EU and globally, registered trademarks in over 40 countries, collaborations with entities such as RegSmart, Zelmic, and AFRY, and a planned production center in Östersund, Auxesis is well-equipped for international expansion. The company has also obtained SME status from the European Medicines Agency (EMA), which strengthens the conditions for successful product development.
Auxesis combines scientific rigor with clear market potential. It is a company that can take a leading position within its niche globally. Our investment is not just about capital – we want to be a long-term partner on their journey,” says Radek Gabor, CEO of Growth By Capital Sweden AB (GBC).
Auxesis was recently valued at between 526 and 598 million SEK by an independent analysis firm. During 2024 and 2025, emissions will be carried out to broaden the ownership base and accelerate the path towards a planned IPO.
A Clear Plan for Growth
With investments in both Etzy AB and Auxesis Pharma Holding AB, GBC demonstrates that the company is rapidly advancing. The strategy is offensive but long-term: to identify companies with innovative strength, build strong partnerships, and support their journey from research and development to international market expansion and an IPO.
About Growth By Capital Sweden AB (GBC)
Growth By Capital Sweden AB (GBC) is a Swedish investment firm focusing on entrepreneur-driven growth companies in life science, energy, and technology. The company combines capital, business expertise, and networks to build internationally successful companies in the long term. GBC is a new but aggressively growing company with strong future ambitions.
Radek Gabor
radek.gabor@gbc.se
Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.
